Physician profile
Katelyn E Mccormack
NPI 1184889057
$130,872.61
in general payments reported to CMS, 2019-2025
72 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $30K · 2023: $26K · 2024: $29K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $17K · Travel and Lodging: $7,516 · Consulting Fee: $2,160 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,203.50 |
| Food and Beverage | $16,567.76 |
| Travel and Lodging | $7,515.76 |
| Consulting Fee | $2,160.00 |
| Education | $274.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $43,915.02 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $23,644.91 | 2021-2025 | Vumerity, Tysabri, Spinraza |
| Genzyme Corporation | $19,656.53 | 2021-2025 | |
| Tg Therapeutics, INC. | $15,947.58 | 2023-2025 | |
| Genentech USA, INC. | $9,691.81 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $2,040.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,638.96 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,207.29 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Ucb, INC. | $1,195.98 | 2021-2025 | Rystiggo, Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $1,003.18 | 2021-2025 | Ingrezza, Ongentys |
| Horizon Therapeutics Plc | $903.55 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $864.93 | 2021-2025 | Ultomiris, Soliris |
| Amgen INC. | $807.89 | 2021-2025 | Uplizna, Tepezza |
| Sk Life Science, INC. | $561.59 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $524.52 | 2021-2022 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $501.12 | 2021-2025 | Onpattro |
| Tanabe Pharma America, INC. | $487.28 | 2021-2025 | Radicava |
| Pfizer INC. | $487.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $363.08 | 2021-2023 | Ponvory |
| Mallinckrodt Hospital Products INC. | $357.52 | 2021-2025 | Acthar |
| Celgene Corporation | $355.70 | 2021-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $261.98 | 2021-2022 | |
| Argenx US, INC. | $236.64 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $229.29 | 2023-2024 | Nuedexta |
| Kyowa Kirin, INC. | $217.09 | 2021-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $208.11 | 2021-2025 | Xeomin, Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $203.45 | 2023-2025 | Hyqvia, Gammagard |
| Catalyst Pharmaceuticals, INC. | $169.18 | 2022-2025 | Firdapse |
| Lilly USA, LLC | $167.37 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Lundbeck LLC | $155.68 | 2023-2025 | Vyepti |
| Genentech, INC. | $150.51 | 2021-2025 | Ocrevus |
| Adamas Pharmaceuticals, INC. | $150.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $149.49 | 2022 | |
| Averitas Pharma INC. | $148.80 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $146.63 | 2021-2022 | |
| Axsome Therapeutics, INC. | $143.31 | 2023-2025 | Sunosi |
| Csl Behring | $143.23 | 2021-2023 | Hizentra |
| Octapharma USA, INC. | $134.24 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Astrazeneca Pharmaceuticals Lp | $104.54 | 2024-2025 | Wainua |
| Harmony Biosciences LLC | $97.23 | 2023-2024 | Wakix |
| Grifols USA, LLC | $95.04 | 2022-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $93.49 | 2022-2025 | Crexont, Rytary, Lyvispah |
| Vanda Pharmaceuticals INC. | $92.75 | 2025 | Ponvory |
| Janssen Biotech, INC. | $88.58 | 2025 | |
| Mdd US Operations, LLC | $85.73 | 2021-2022 | |
| Banner Life Sciences, LLC | $85.02 | 2021-2022 | |
| Greenwich Biosciences, INC. | $79.21 | 2021 | |
| Ge Healthcare | $78.76 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $74.50 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $64.10 | 2021 | |
| Mylan Specialty L.P. | $57.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $50.02 | 2022-2023 | Quviviq |
| Neurelis, INC. | $46.47 | 2024 | Valtoco |
| Scilex Pharmaceuticals INC. | $45.97 | 2021-2022 | |
| Invivyd INC | $43.42 | 2025 | Pemgarda |
| Acorda Therapeutics, INC | $42.17 | 2023 | Ampyra, Inbrija |
| Ipsen Biopharmaceuticals, INC | $41.61 | 2021-2025 | Dysport |
| Impel Pharmaceuticals INC. | $33.80 | 2022-2023 | Trudhesa |
| Alkermes, INC. | $32.57 | 2025 | Vivitrol |
| Upsher-Smith Laboratories LLC | $30.54 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.82 | 2022 | |
| Ani Pharmaceuticals, INC. | $26.64 | 2022 | |
| Itf Therapeutics LLC | $26.41 | 2025 | |
| Pharmacosmos Therapeutics INC. | $25.04 | 2025 | Monoferric |
| Kedrion Biopharma, INC. | $21.94 | 2024 | Kedrab, Koate, Gammaked |
| Xeris Pharmaceuticals, INC. | $19.53 | 2022 | |
| Otter Pharmaceuticals, LLC | $18.96 | 2025 | Sympazan |
| Sobi, INC | $17.89 | 2021 | |
| Livanova USA, INC. | $16.70 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Cycle Pharmaceuticals INC | $16.27 | 2025 | Bafiertam, Tascenso Odt |
| Amylyx Pharmaceuticals, INC. | $12.75 | 2023 | Relyvrio |
| 3b Medical, INC. | $8.47 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.